Next-Gen Immunotherapies for Cancer
What is the future of next-generation immunotherapies for cancer ?
Date: Monday, 25 August 2025 5 pm CET
Speakers: Pierre Belichard (CEO Enterome) and Phi l'Huillier (CEO Scancell)
Moderator: Chris Maggos (Cohesion Bureau)
Enterome and Scancell have reached positive Phase 2 milestones with a new generation of active immunotherapies to treat melanoma and blood cancers, respectively. Their highly differentiated approaches offer insights and strategies for harnessing the immune system more effectively.